Thermo Fisher Scientific (NYSE:TMO) announced a new set of solutions to support adeno-associated viral (AAV) manufacturing.
AAV, a non-pathogenic virus capable of infecting cells at various stages of growth, has become a preferred “viral vector” for delivering gene therapies, although the scalability of AAV remains a challenge.
According to a news release, Thermo Fisher designed its new media panel, gene kit and advanced purification process to produce higher quality viral vectors, simplify the purification process and result in higher yield AAV production.
The Gibco viral vector HEK media panel covers a variety of HEK293 cell types, Thermo Fisher said, with no ties to specific transfection reagents or techniques. Its ready-to-use formulations can help AAV developers identify an optimal formulation for the target cell line.
Applied Biosystems’ resDNASEQ quantitative plasmid DNA kanamycin resistance gene kit offers an all-in-one option for the precise and rapid measurement of residual plasmid DNA, including a highly sensitive multiplex qPCR assay with all reagents and optimized sample prep options to deliver results in under five hours.
Finally, Thermo Fisher’s Poros CaptureSelect AAV affinity purification resins, the latest addition to a portfolio of viral vector solutions, can improve downstream processing of viral vectors through the reduction of purification steps while offering scalability.
“Despite the immense promise of gene therapy, robustness and yield continue to pose challenges in the manufacturing process,” Thermo Fisher Scientific VP & GM of cell & gene therapy Betty Woo said in the release. “Growth media that maximizes viral titer and rapid analytical tests contribute to cost-effective and efficient AAV production. Our expanding gene therapy portfolio is designed for a smooth ramp-up to clinical production and we have made focused investments to ensure we stay ahead of commercial demand.
“Ultimately, our innovative solutions are developed to expedite the delivery of safer therapies to patients.”